These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32383205)

  • 1. European perspective of perampanel response in people with Intellectual Disability.
    Allard J; Henley W; Snoeijen-Schouwenaars F; van Ool J; Tan I; Jurgen Schelhaas H; Majoie MHJM; Hudson S; McLean B; Shankar R
    Acta Neurol Scand; 2020 Sep; 142(3):255-259. PubMed ID: 32383205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perampanel in the general population and in people with intellectual disability: Differing responses.
    Shankar R; Henley W; Wehner T; Wiggans C; McLean B; Pace A; Mohan M; Sadler M; Doran Z; Hudson S; Allard J; Sander JW
    Seizure; 2017 Jul; 49():30-35. PubMed ID: 28552718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eslicarbazepine acetate response in intellectual disability population versus general population.
    Allard J; Lawthom C; Henley W; Mclean B; Hudson S; Tittensor P; Rajakulendran S; Ellawela S; Pace A; Shankar R
    Acta Neurol Scand; 2021 Mar; 143(3):256-260. PubMed ID: 33131083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of perampanel in patients with intellectual disability and epilepsy.
    Snoeijen-Schouwenaars FM; van Ool JS; Tan IY; Schelhaas HJ; Majoie MH
    Epilepsy Behav; 2017 Jan; 66():64-67. PubMed ID: 28038388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perampanel-induced hair curling in a patient with epilepsy associated with Pitt Hopkins syndrome.
    Calle-Lopez Y; Kotagal P; Knight EP
    Epileptic Disord; 2019 Oct; 21(5):479-482. PubMed ID: 31638579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural changes in patients with intellectual disability treated with perampanel.
    Andres E; Kerling F; Hamer H; Kasper B; Winterholler M
    Acta Neurol Scand; 2017 Dec; 136(6):645-653. PubMed ID: 28568478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum.
    Doran Z; Shankar R; Keezer MR; Dale C; McLean B; Kerr MP; Devapriam J; Craig J; Sander JW
    Eur J Neurol; 2016 Jul; 23(7):1152-7. PubMed ID: 27106363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study.
    Shah E; Reuber M; Goulding P; Flynn C; Delanty N; Kemp S
    Seizure; 2016 Jan; 34():1-5. PubMed ID: 26615577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel for the treatment of epilepsy; Longitudinal actuarial analysis and dose responses based on monthly outcomes.
    Stavropoulos I; Louden W; Queally C; Adcock J; Tristram M; Neale M; Moran N; Flores L L; Nashef L; Richardson MP; Bell C; Slaght S; Aram J; Rayner N; Powell R; Mead A; Sen A; Elwes R
    Seizure; 2019 Jul; 69():125-132. PubMed ID: 31026743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and patterns of anti-epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities.
    O'Dwyer M; Peklar J; Mulryan N; McCallion P; McCarron M; Henman MC
    J Intellect Disabil Res; 2018 Mar; 62(3):245-261. PubMed ID: 29314463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study.
    Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T
    Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel-induced weight gain depends on level of intellectual disability and its serum concentration.
    Iwaki H; Jin K; Sugawara N; Nakasato N; Kaneko S
    Epilepsy Res; 2019 May; 152():1-6. PubMed ID: 30852339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours.
    Maurousset A; Limousin N; Praline J; Biberon J; Corcia P; De Toffol B
    Epilepsy Behav; 2016 Aug; 61():237-241. PubMed ID: 27393930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
    Sun JJ; Perera B; Henley W; Angus-Leppan H; Sawhney I; Watkins L; Purandare KN; Eyeoyibo M; Scheepers M; Lines G; Winterhalder R; Ashby S; De Silva R; Miller J; Philpott DE; Ashwin C; Howkins J; Slater H; Medhurst D; Shankar R
    J Neurol; 2022 May; 269(5):2750-2760. PubMed ID: 35067759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy.
    Gil-Nagel A; Burd S; Toledo M; Sander JW; Lebedeva A; Patten A; Laurenza A;
    Seizure; 2018 Jan; 54():61-66. PubMed ID: 29288911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center.
    Wehner T; Mannan S; Turaga S; Vallabhaneni K; Yip HM; Wiggans C; Shankar R; Duncan JS; Sander JW
    Epilepsy Behav; 2017 Aug; 73():106-110. PubMed ID: 28624720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The retention of lacosamide in patients with epilepsy and intellectual disability in three specialised institutions.
    Brenner J; Majoie HJM; van Beek S; Carpay JA
    Seizure; 2017 Nov; 52():123-130. PubMed ID: 29031193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
    Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
    Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.